News
Partnership for Safe Medicines Statement on FDA Authorization of Colorado”s Section 804 Importation Program
“Colorado is now poised to repeat Florida’s failed attempt to implement Canadian drug importation,” said PSM Executive Director Shabbir Imber Safdar. “Since beginning their program in 2019, Florida has spent $132 million and still not imported a single unit of medicine, proving that these bulk importation programs are not reducing drug costs for Americans.”
[...]Fishy Peptide Freight: What Q1 2026 import data reveals
As the popularity of peptides skyrockets, consumers should be asking questions about where their drugs come from. Here’s what we found in shipment data for peptides in Q1.
[...]June 8, 2026: Reckless physicians prescribing experimental, black market weight loss drugs: “Why are we waiting?”
Retatrutide, an experimental weight loss drug that hasn’t been submitted for FDA-approval, is being prescribed in weight loss clinics and med spas across the country.
[...]Prescription Drug Freight Fraud, June 2026 report
March and April 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
[...]Fake medicines in Mexico, November 2025 – May 2026
Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.
[...]June 1, 2026: Up to 18 years for counterfeit pill conspirators in Massachusetts
The scheme, which produced counterfeit oxycodone, Adderall, and Xanax, is linked to over a dozen deaths, according to prosecutors.
[...]May 26, 2026: Maryland PDAB passes a price cap on Ozempic, as Virginia’s governor questions board efficacy
Ozempic, the second drug that the state has set an upper payment limit on, will be capped at $274 for a 30-day supply.
[...]May 18, 2026: FDA warns 503B compounding pharmacy for producing tirzepatide after shortage ended
The ProRx warning letter signals increased FDA scrutiny of compounded weight loss product that are not intended to be compounded in the US.
[...]Safety risks in the GLP-1 market: an update on weight loss medication, May 2026
Criminal counterfeiters are exploiting Americans’ demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide, while compounders, telehealth companies, and med spas strain and skirt public health measures to meet high demand.
[...]An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper?
An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper? On May 18, 2026, PSM sent a letter rebuking the Arkansas Democrat-Gazette for selling ad space to a Canadian online pharmacy last month. The advertisement, which promised to “save buyer’s up to 80% on their prescription drugs,” promotes…
[...]